Innovative Therapeutic Strategies for Effective Treatment of Brain Metastases
Authors:
- Malcolm LimMalcolm Lim
- Simon PuttickSPSimon Puttick
- Zachary H. HoustonZachary H. Houston
- Kristofer J. ThurechtKristofer J. Thurecht
- Priyakshi Kalita-De CroftPCPriyakshi Kalita-De Croft
- Stephen MahlerSMStephen Mahler
- Stephen E. RoseSRStephen E. Rose
- Rosalind L. JeffreeRJRosalind L. Jeffree
- Roberta MazzieriRMRoberta Mazzieri
- Riccardo DolcettiRiccardo Dolcetti
- Sunil R. LakhaniSLSunil R. Lakhani
- Jodi M. SaunusJSJodi M. Saunus
Open Access
- 14 March 2019
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (6) , 1280
Abstract
Brain metastases are the most prevalent of intracranial malignancies. They are associated with a very poor prognosis and near 100% mortality. This has been the case for decades, largely because we lack effective therapeutics to augment surgery and radiotherapy. Notwithstanding improvements in the precision and efficacy of these life-prolonging treatments, with no reliable options for adjunct systemic therapy, brain recurrences are virtually inevitable. The factors limiting intracranial efficacy of existing agents are both physiological and molecular in nature. For example, heterogeneous permeability, abnormal perfusion and high interstitial pressure oppose the conventional convective delivery of circulating drugs, thus new delivery strategies are needed to achieve uniform drug uptake at therapeutic concentrations. Brain metastases are also highly adapted to their microenvironment, with complex cross-talk between the tumor, the stroma and the neural compartments driving speciation and drug resistance. New strategies must account for resistance mechanisms that are frequently engaged in this milieu, such as HER3 and other receptor tyrosine kinases that become induced and activated in the brain microenvironment. Here, we discuss molecular and physiological factors that contribute to the recalcitrance of these tumors, and review emerging therapeutic strategies, including agents targeting the PI3K axis, immunotherapies, nanomedicines and MRI-guided focused ultrasound for externally controlling drug delivery.Keywords
This publication has 182 references indexed in Scilit:
- Incidence and time trends of brain metastases admissions among breast cancer patients in SwedenBritish Journal of Cancer, 2012
- Current strategies in the surgical management of cerebral metastases: an evidence-based reviewJournal of Clinical Neuroscience, 2011
- Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasisClinical & Experimental Metastasis, 2010
- Pericytes are required for blood–brain barrier integrity during embryogenesisNature, 2010
- Genome remodelling in a basal-like breast cancer metastasis and xenograftNature, 2010
- Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[11C]verapamil PETEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- Brain metastases admissions in Sweden between 1987 and 2006British Journal of Cancer, 2009
- HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary TumorsClinical Cancer Research, 2009
- Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep‐2British Journal of Pharmacology, 2008
- Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3Nature, 2007